anyone previously in critical or high dependency hospital care from COVID-19

Version Control

Version Date Author Notes 1.5 July 2022 Care in the

1.6 Nov 2022 Commu nity Care in the Commu nity

1. Added latest eligibility criteria 2. Added considerations for holiday period 3. Added pharmacist-only reclassification 4. Added advice supporting increased use of Paxlovid 5. Added guidance for dosing in chronic kidney disease (CKD) 6. Moderated advice on management of drug interactions with

Paxlovid 7. Updated links to key resources 8. Updated advice on rebound infection and re-infection 9. Strengthened advice on timeliness of delivery 10. Clarified process for reporting COVID-19 positive results 11. Added advance prescription guidance 12. Clarified how recent renal function tests must be 13. Clarified eligibility criteria 14. Added not for use with Long COVID

1 Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine. 2022 Apr 14;386(15):1397-408. 2 Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, Du J. molnupiravir for oral

treatment of Covid-19 in nonhospitalized patients. New England Journal of Medicine. 2022 Feb 10;386(6):509-20. 3 a rural area is defined by the Pharmaceutical Schedule as an area locally determined as rural by the appropriate DHB.